Current status of intrathecal chemotherapy for human meningeal neoplasms.
Progress in clinical intrathecal chemotherapy has been slow, and a number of new problems have been encountered. The most significant recent developments include the: 1) success of adjunctive intrathecal chemotherapy in the prevention of meningeal leukemia; 2) recognition and characterization of a necrotizing leukoencephalopathic reaction associated with intrathecal methotrexate therapy; 3) demonstration of the efficacy of intraventricular chemotherapy via an Ommaya reservoir; 4) delineation of the clinical pharmacology of intralumbar and intraventricular methotrexate; and 5) identification of an urgent need for new drugs and techniques for intrathecal administration.
D000818:Animals; D000970:Antineoplastic Agents / Q000008:administration & dosage*; D001100:Arachnoiditis / Q000139:chemically induced; D002648:Child; D006801:Humans; D007276:Injections, Intraventricular / Q000379:methods; D007278:Injections, Spinal; D007938:Leukemia / Q000188:drug therapy; D007968:Leukoencephalopathy, Progressive Multifocal / Q000139:chemically induced; D008577:Meningeal Neoplasms / Q000134:cerebrospinal fluid / Q000188:drug therapy*; D008727:Methotrexate / Q000008:administration & dosage* / Q000009:adverse effects / Q000134:cerebrospinal fluid; D012107:Research Design
D000970:Antineoplastic Agents; D008727:Methotrexate